{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:25:48Z","timestamp":1792113948886,"version":"4.4.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.nmd.2021.07.008","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T05:27:49Z","timestamp":1627450069000},"page":"1070-1080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Newborn screening of neuromuscular diseases"],"prefix":"10.1016","volume":"31","author":[{"given":"Tamara","family":"Dangouloff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Boemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2021.07.008_bib0001","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/adc.51.4.249","article-title":"Screening for Duchenne muscular dystrophy","volume":"51","author":"Dubowitz","year":"1976","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.nmd.2021.07.008_bib0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/jmg.2.1.12","article-title":"Familial low birthweight dwarfism with an unusual facies and a skin eruption","volume":"2","author":"Dubowitz","year":"1965","journal-title":"J Med Genet"},{"key":"10.1016\/j.nmd.2021.07.008_bib0003","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jpeds.2009.02.007","article-title":"Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)","volume":"155","author":"Ciafaloni","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2021.07.008_bib0004","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pediatrneurol.2015.06.002","article-title":"Delay in diagnosis of spinal muscular atrophy: a systematic literature review","volume":"53","author":"Lin","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.nmd.2021.07.008_bib0005","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","article-title":"Timing of diagnosis of patients with Pompe disease: data from the Pompe registry","volume":"161A","author":"Kishnani","year":"2013","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.nmd.2021.07.008_bib0006","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0303-8467(93)90004-Z","article-title":"Delay in diagnosis of X-linked adrenoleukodystrophy","volume":"95","author":"van Geel","year":"1993","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.nmd.2021.07.008_bib0007","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.nmd.2021.07.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2015.10.078","article-title":"Very early treatment for infantile-onset pompe disease contributes to better outcomes","volume":"169","author":"Yang","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2021.07.008_bib0009","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamaneurol.2016.4069","article-title":"Improved muscular weakness during asthma exacerbation","volume":"74","author":"Delstanche","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2021.07.008_bib0010","series-title":"Principles and practice of screening","author":"Wilson","year":"1968"},{"key":"10.1016\/j.nmd.2021.07.008_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/ijns7010015","article-title":"Neonatal screening in europe revisited: an ISNS perspective on the current state and developments since 2010","volume":"7","author":"Loeber","year":"2021","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.nmd.2021.07.008_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.nmd.2021.07.008_bib0013","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","article-title":"New treatments in spinal muscular atrophy: an overview of currently available data","volume":"21","author":"Ramdas","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nmd.2021.07.008_bib0014","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2021.07.008_bib0015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.nmd.2021.07.008_bib0016","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in Type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2021.07.008_bib0017","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/13543784.2021.1904889","article-title":"Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities","volume":"30","author":"Servais","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.nmd.2021.07.008_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2017.06.042","article-title":"Presymptomatic diagnosis of spinal muscular atrophy through newborn screening","volume":"190","author":"Chien","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2021.07.008_bib0019","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/gim.2017.152","article-title":"Pilot study of population-based newborn screening for spinal muscular atrophy in New York state","volume":"20","author":"Kraszewski","year":"2018","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.nmd.2021.07.008_bib0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ijns7010020","article-title":"A voluntary statewide newborn screening pilot for spinal muscular atrophy: results from early check","volume":"7","author":"Kucera","year":"2021","journal-title":"Int J Neonatal Screen"},{"issue":"1","key":"10.1016\/j.nmd.2021.07.008_bib0021","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","article-title":"Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years","volume":"16","author":"Vill","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2021.07.008_bib0022","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.nmd.2019.02.003","article-title":"Newborn screening for SMA in Southern Belgium","volume":"29","author":"Boemer","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.07.008_bib0023","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41436-019-0673-0","article-title":"The implementation of newborn screening for spinal muscular atrophy: the Australian experience","volume":"22","author":"Kariyawasam","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2021.07.008_bib0024","first-page":"1","article-title":"Newborn screening for spinal muscular atrophy: Ontario testing and follow-up recommendations","author":"McMillan","year":"2020","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.nmd.2021.07.008_bib0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/ijns5040041","article-title":"A novel system for spinal muscular atrophy screening in newborns: Japanese pilot study","volume":"5","author":"Shinohara","year":"2019","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.nmd.2021.07.008_bib0026","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.07.008_bib0027","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.07.008_bib0028","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41436-020-0824-3","article-title":"Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy","volume":"22","author":"Kay","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2021.07.008_bib0029","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s41436-020-0887-1","article-title":"Correspondence on: \u201cDiscrepancy in Spinal Muscular Atrophy Incidence findings in newborn screening programs: the influence of carrier screening?\u201d by Kay et al","volume":"22","author":"Dangouloff","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2021.07.008_bib0030","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41436-020-01080-y","article-title":"Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction","volume":"23","author":"Li","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2021.07.008_bib0031","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1177\/0883073816665549","article-title":"Cognitive development in infantile-onset pompe disease under very early enzyme replacement therapy","volume":"31","author":"Lai","year":"2016","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2021.07.008_bib0032","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1542\/peds.2007-2222","article-title":"Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program","volume":"122","author":"Chien","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.nmd.2021.07.008_bib0033","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ymgme.2009.12.014","article-title":"Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program","volume":"99","author":"Labrousse","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2021.07.008_bib0034","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ymgme.2012.04.013","article-title":"Algorithm for Pompe disease newborn screening: results from the Taiwan screening program","volume":"106","author":"Chiang","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2021.07.008_bib0035","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ajmg.a.36197","article-title":"A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment","volume":"164A","author":"Yang","year":"2014","journal-title":"Am J Med Genet A"},{"issue":"1","key":"10.1016\/j.nmd.2021.07.008_bib0036","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/ijns6010011","article-title":"Lessons learned from Pompe disease newborn screening and follow-up","volume":"6","author":"Klug","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.nmd.2021.07.008_bib0037","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/ijns6010004","article-title":"Newborn screening for Pompe disease in Illinois: experience with 684,290 infants","volume":"6","author":"Burton","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.nmd.2021.07.008_bib0038","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/ijns6040089","article-title":"Newborn screening for Pompe disease: Pennsylvania experience","volume":"6","author":"Ficicioglu","year":"2020","journal-title":"Int J Neonatal Screen"},{"issue":"1","key":"10.1016\/j.nmd.2021.07.008_bib0039","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/ijns6010009","article-title":"The first year experience of newborn screening for Pompe disease in California","volume":"6","author":"Tang","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.nmd.2021.07.008_bib0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ymgme.2017.03.001","article-title":"Newborn screening for six lysosomal storage disorders in a cohort of Mexican patients: three-year findings from a screening program in a closed Mexican health system","volume":"121","author":"Navarrete-Martinez","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2021.07.008_bib0041","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s10038-019-0603-7","article-title":"Newborn screening for Pompe disease in Japan: report and literature review of mutations in the GAA gene in Japanese and Asian patients","volume":"64","author":"Momosaki","year":"2019","journal-title":"J Hum Genet"},{"key":"10.1016\/j.nmd.2021.07.008_bib0042","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgmr.2017.06.006","article-title":"Investigation of newborns with abnormal results in a newborn screening program for four lysosomal storage diseases in Brazil","volume":"12","author":"Bravo","year":"2017","journal-title":"Mol Genet Metab Reports"},{"key":"10.1016\/j.nmd.2021.07.008_bib0043","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/0009922809347777","article-title":"Duchenne muscular dystrophy: a 30-year population-based incidence study","volume":"49","author":"Dooley","year":"2010","journal-title":"Clin Pediatr (Phila)"},{"issue":"1","key":"10.1016\/j.nmd.2021.07.008_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/jpm9010001","article-title":"Restoring dystrophin expression in Duchenne muscular dystrophy: current status of therapeutic approaches","volume":"9","author":"Shimizu-Motohashi","year":"2019","journal-title":"J Pers Med"},{"key":"10.1016\/j.nmd.2021.07.008_bib0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12519-017-0036-3","article-title":"Newborn screening for Duchenne muscular dystrophy in China: follow-up diagnosis and subsequent treatment","volume":"13","author":"Ke","year":"2017","journal-title":"World J Pediatr"},{"key":"10.1016\/j.nmd.2021.07.008_bib0046","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.07.008_bib0047","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/gte.1998.2.55","article-title":"Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus","volume":"2","author":"Drousiotou","year":"1998","journal-title":"Genet Test"},{"key":"10.1016\/j.nmd.2021.07.008_bib0048","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","article-title":"Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK)","volume":"21","author":"Moat","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.nmd.2021.07.008_bib0049","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mus.24880","article-title":"Twenty-year follow-up of newborn screening for patients with muscular dystrophy","volume":"53","author":"Chung","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.008_bib0050","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(88)90414-X","article-title":"Gene studies in newborn males with Duchenne muscular dystrophy detected by neonatal screening","volume":"2","author":"Greenberg","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2021.07.008_bib0051","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.nmd.2013.05.008","article-title":"195th ENMC International Workshop: newborn screening for Duchenne muscular dystrophy 14-16th December 2012, Naarden, The Netherlands","volume":"23","author":"Ellis","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.07.008_bib0052","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/adc.54.5.362","article-title":"Creatine phosphokinase levels in the newborn and their use in screening for Duchenne muscular dystrophy","volume":"54","author":"Drummond","year":"1979","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.nmd.2021.07.008_bib0053","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(89)92170-3","article-title":"Duchenne muscular dystrophy: neonatal screening and prenatal diagnosis","volume":"1","author":"Plauchu","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2021.07.008_bib0054","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/mus.880090103","article-title":"Screening for Duchenne muscular dystrophy: an improved screening test for creatine kinase and its application in an infant screening program","volume":"9","author":"Scheuerbrandt","year":"1986","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.008_bib0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000369343","article-title":"Prevalence of muscular dystrophies: a systematic literature review","volume":"43","author":"Theadom","year":"2014","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.nmd.2021.07.008_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2021.03.024","article-title":"Myotonic dystrophy type 1 drug development: a pipeline toward the market","author":"Pascual-Gilabert","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.nmd.2021.07.008_bib0057","doi-asserted-by":"crossref","first-page":"e1045","DOI":"10.1212\/WNL.0000000000011425","article-title":"Population-based prevalence of Myotonic dystrophy Type 1 using genetic analysis of statewide blood screening program","volume":"96","author":"Johnson","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.008_bib0058","series-title":"GeneReviews\u00ae [Internet]","article-title":"Krabbe disease","author":"Orsini","year":"1993"},{"key":"10.1016\/j.nmd.2021.07.008_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/mgme.2000.2990","article-title":"Krabbe disease: genetic aspects and progress toward therapy","volume":"70","author":"Wenger","year":"2000","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2021.07.008_bib0060","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1212\/WNL.0000000000004427","article-title":"Stem cell transplantation in Krabbe disease: new truths discovered and opinions change","volume":"89","author":"Graf","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.008_bib0061","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/GIM.0b013e3181a16e04","article-title":"The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York","volume":"11","author":"Duffner","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2021.07.008_bib0062","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/gim.2016.35","article-title":"Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York State","volume":"18","author":"Wasserstein","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2021.07.008_bib0063","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/gim.2015.211","article-title":"Newborn screening for Krabbe disease in New York State: the first eight years\u2019 experience","volume":"18","author":"Orsini","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2021.07.008_bib0064","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/gim.2017.194","article-title":"Precision newborn screening for lysosomal disorders","volume":"20","author":"Minter Baerg","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2021.07.008_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijns7020024","article-title":"Newborn screening for Krabbe disease-Illinois experience: role of psychosine in diagnosis of the disease","volume":"7","author":"Basheeruddin","year":"2021","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.nmd.2021.07.008_bib0066","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/dmcn.14258","article-title":"Ethical issues with testing and treatment for Krabbe disease","volume":"61","author":"Ehmann","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2021.07.008_bib0067","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11940-019-0605-y","article-title":"The landscape of hematopoietic stem cell transplant and gene therapy for X-linked adrenoleukodystrophy","volume":"21","author":"Mallack","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.nmd.2021.07.008_bib0068","unstructured":"Health Resources and Services Administration (HRSA). Baby's first test 2020. https:\/\/www.babysfirsttest.org."},{"key":"10.1016\/j.nmd.2021.07.008_bib0069","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MED.0000000000000515","article-title":"Adrenoleukodystrophy in the era of newborn screening","volume":"27","author":"Eng","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.nmd.2021.07.008_bib0070","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ajmg.a.61171","article-title":"A report on state-wide implementation of newborn screening for X-linked Adrenoleukodystrophy","volume":"179","author":"Wiens","year":"2019","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.nmd.2021.07.008_bib0071","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20356","article-title":"Evaluation of X-linked adrenoleukodystrophy newborn screening in North Carolina","volume":"3","author":"Lee","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.nmd.2021.07.008_bib0072","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3389\/fcell.2020.00499","article-title":"Adrenoleukodystrophy newborn screening in the Netherlands (SCAN Study): the X-factor","volume":"8","author":"Barendsen","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.nmd.2021.07.008_bib0073","unstructured":"National Librairy of Medicine N. Clinical trial 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02952482?term=NCT02952482&draw=2&rank=1."},{"key":"10.1016\/j.nmd.2021.07.008_bib0074","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/jnr.23792","article-title":"Gene therapy for metachromatic leukodystrophy","volume":"94","author":"Rosenberg","year":"2016","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.nmd.2021.07.008_bib0075","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.nmd.2021.07.008_bib0076","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41436-020-01017-5","article-title":"Toward newborn screening of metachromatic leukodystrophy: results from analysis of over 27,000 newborn dried blood spots","volume":"23","author":"Hong","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2021.07.008_bib0077","article-title":"AVXS-101 gene-replacement therapy in presymptomatic spinal muscular atrophy: SPR1NT study update","author":"Strauss","year":"2019","journal-title":"Am Acad Neurol"},{"key":"10.1016\/j.nmd.2021.07.008_bib0078","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nmd.2019.11.002","article-title":"244th ENMC international workshop: newborn screening in spinal muscular atrophy May 10\u201312, 2019, Hoofdorp, The Netherlands","volume":"30","author":"Dangouloff","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.nmd.2021.07.008_bib0079","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","article-title":"Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments","volume":"16","author":"Dangouloff","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2021.07.008_bib0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2021.07.008_bib0081","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JND-190468","article-title":"Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2","volume":"7","author":"Glascock","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2021.07.008_bib0082","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2021.07.008_bib0083","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-82725-z","article-title":"Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy","volume":"11","author":"Beckers","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmd.2021.07.008_bib0084","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fnmol.2020.610964","article-title":"The neuromuscular junction in health and disease: molecular mechanisms governing synaptic formation and homeostasis","volume":"13","author":"Rodr\u00edguez Cruz","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.nmd.2021.07.008_bib0085","article-title":"Late-onset riboflavin transporter deficiency: a treatable mimic of various motor neuropathy aetiologies","author":"Carreau","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2021.07.008_bib0086","doi-asserted-by":"crossref","first-page":"e1852","DOI":"10.1212\/WNL.0000000000007319","article-title":"X-linked myotubular myopathy: a prospective international natural history study","volume":"92","author":"Annoussamy","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.008_bib0087","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1212\/WNL.0000000000004415","article-title":"A natural history study of X-linked myotubular myopathy","volume":"89","author":"Amburgey","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.008_bib0088","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JND-200479","article-title":"Use of the children's hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND) in X-linked myotubular myopathy: content validity and psychometric performance","volume":"8","author":"Duong","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2021.07.008_bib0089","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1089\/hum.2020.217","article-title":"Re: \u201cmoving forward after two deaths in a gene therapy trial of myotubular myopathy\u201d by Wilson and Flotte","volume":"31","author":"Shieh","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.nmd.2021.07.008_bib0090","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3233\/JND-180309","article-title":"Centronuclear myopathies under attack: a plethora of therapeutic targets","volume":"5","author":"Tasfaout","year":"2018","journal-title":"J Neuromuscul Dis"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621001905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621001905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:12:26Z","timestamp":1760775146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896621001905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":90,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0960896621001905"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2021.07.008","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Newborn screening of neuromuscular diseases","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2021.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}